Does adding stem cells to a ChondroFiller injection actually help?

For patients with significant knee cartilage loss, the practical question is straightforward: does adding stem cells to a ChondroFiller injection actually produce better results than either treatment on its own? On the current evidence, the answer appears to be yes — though the data are early and honest caveats apply.

The most direct evidence comes from a prospective controlled trial published in June 2025 by Weninger, Reitböck and colleagues at Avancell Medical in Vienna. The study enrolled 25 patients with Kellgren-Lawrence Grade IV knee osteoarthritis and compared autologous MSC concentrate alone (n=12) against ChondroFiller liquid collagen combined with autologous MSC concentrate (n=13). Both groups improved, but the combination arm outperformed MSC-only treatment across all five KOOS subscales at two months, with the difference reaching statistical significance (p<0.01). The combination group also showed a greater reduction in MMP-13 — a biomarker of active cartilage breakdown — and less bone marrow oedema on MRI. No serious adverse events occurred in either group.

Those findings are biologically credible. A 2025 ex vivo study using 61 femoral condyle explants from knee arthroplasty patients directly compared ChondroFiller alone against ChondroFiller combined with MSCs: the scaffold alone produced a 2.4-fold increase in DNA content by day 14, indicating meaningful host cell recruitment, while adding MSCs further enhanced collagen deposition and glycosaminoglycan production beyond what the scaffold achieved unassisted.

The honest limitations matter, however. Two months is a short follow-up window for a Grade IV knee, and 25 participants is a small sample. No randomised controlled trial has yet compared ChondroFiller plus MSCs directly against ChondroFiller alone — so the specific contribution of each component to the combination's advantage remains to be confirmed in larger, longer studies.

How the ChondroFiller injection works as a collagen scaffold

The scaffold side of the combination has a well-documented mechanism. ChondroFiller is a CE-marked Class III medical device — a two-component type I collagen hydrogel delivered, in current clinical practice, as an ultrasound-guided outpatient injection placed directly into the focal cartilage defect.

Once inside the joint, the two components mix and polymerise rapidly, forming a stable three-dimensional gel matrix over the damaged articular surface within minutes. This does two things: it physically covers and protects the defect from further mechanical wear, and it provides a porous collagen lattice into which the patient's own progenitor cells can migrate and begin forming repair tissue. The process is called matrix-induced chondrogenesis — the scaffold recruits rather than replaces cells, relying on the patient's biology to drive tissue formation.

Clinical data from ChondroFiller as a standalone injection support this picture. A multicentre randomised study published in 2016 (n=13) showed statistically significant IKDC improvements at 3, 6, and 12 months, with MRI confirming progressive maturation of repair tissue over 52 weeks and no adverse events recorded. A 2024 Bulgarian cohort of 17 patients (mean age 31) replicated these gains — Lysholm and IKDC scores both improved significantly from baseline through 12 months, with a functional plateau emerging between the 6- and 12-month timepoints.

One early-phase caveat applies. A 2024 in-vitro biomechanical study found the gel does not adequately shield the opposing cartilage surface under full cyclic loading in the early post-implant period, due to initial scaffold instability — which is why protected weight-bearing for approximately six weeks is recommended after injection.

What MSCs add that the scaffold alone cannot provide

Injecting MSCs into the knee without a scaffold carries a practical limitation: the cells disperse rapidly through the joint cavity and are cleared within hours, reducing their window of action at the defect site. The collagen matrix solves this directly — it physically traps the stem cell concentrate within the lesion and holds it there, turning a fleeting cell infusion into a sustained biological presence at the repair site.

Once retained, MSCs contribute what ChondroFiller cannot provide independently: active anti-inflammatory messenger signals and direct extracellular matrix synthesis. A phase II triple-blinded RCT (n=40) of allogeneic adipose-derived MSCs injected intra-articularly for knee OA demonstrated this biology clearly — IL-10 rose significantly within one week, circulating T-cell populations declined over six months, systemic inflammatory markers fell by three months, and MRI showed a slight increase in medial tibial cartilage thickness. These effects arise primarily from paracrine signalling: MSCs modulate the immune environment of the joint, interrupting the inflammatory cascade that accelerates cartilage loss — something an acellular scaffold cannot independently achieve.

The additive tissue-building effect was confirmed in the 2025 ex vivo model discussed in the opening section: MSC-combined groups produced measurably greater collagen and glycosaminoglycan output than the scaffold alone, indicating the cells are actively synthesising repair matrix rather than passively surviving within the collagen lattice.

MSCs for this combination can be sourced autologously from bone marrow aspirate concentrate (BMAC), infrapatellar fat pad, adipose tissue, or synovium — each carrying different cellular characteristics and harvest considerations. The optimal source specifically for the ChondroFiller injection combination has not yet been defined by randomised trial evidence.

The evidence base: what studies show and where the gaps are

Taken together, the available evidence forms a coherent but incomplete picture — and it is worth being clear about what each tier establishes.

The Weninger et al. 2025 prospective controlled trial is the only study that directly tests the combination against a clinical comparator. Its structure — randomised assignment, an active control arm, validated patient-reported outcomes, biomarker endpoints, and MRI assessment — places it above cohort data in evidential weight. The honest constraint is its size and horizon: 25 patients assessed at two months cannot confirm structural durability over years, nor identify which patient subgroups respond best.

The 2025 ex vivo platform provides biological plausibility for those clinical signals, without itself generating patient outcomes data. Below that, the 2016 multicentre RCT (n=13) and the 2024 cohort (n=17) establish that ChondroFiller injection as a standalone produces consistent IKDC and Lysholm gains through 12 months — but no adequately powered trial of the knee injection route has reached 24 or 36 months, so long-term structural durability cannot be confirmed from these data alone.

For a longer-range indication of what a scaffold-plus-biologic-concentrate approach can achieve, a 14-year follow-up of hyaluronic acid scaffold combined with bone marrow aspirate concentrate (HA-BMAC, n=26) reported durable KOOS Pain scores of 92 and only three treatment failures — suggesting the paradigm can hold over time, though this was a different product delivered surgically rather than by injection.

The single most important evidence gap remains unfilled: no randomised trial has yet compared the combination against ChondroFiller injection alone. The 2025 Vienna study established superiority over MSCs delivered without a scaffold; the incremental benefit of adding MSCs to an optimally placed ChondroFiller injection is the question a future head-to-head trial will need to answer.

Who is suitable for this combination and who is not

The patient profile in the 2025 Vienna trial is worth noting upfront: Kellgren-Lawrence Grade IV knee OA sits at the severe end of the structural damage spectrum — a population that would typically be considered for joint replacement rather than cartilage regeneration. Meaningful KOOS improvements at two months are encouraging, but this evidence cannot be extrapolated straightforwardly to the full range of patients who might consider the combination.

The ChondroFiller injection evidence base covers focal chondral defects up to approximately 3 cm² (extendable to 6 cm² per clinical evaluation data). Patients with diffuse, multi-compartmental cartilage loss are generally outside the scope of regenerative approaches; at that stage, the pathway shifts towards alignment correction or joint replacement rather than scaffold-based repair.

Within the focal-defect group, the patients who appear to do best share a recognisable profile in the literature: younger than approximately 50–55, a discrete and symptomatic lesion, preserved or correctably malaligned joint mechanics, and no prior failed marrow-stimulation procedure — which can damage the subchondral bone plate and reduce the quality of the repair bed. Pre-existing severe structural change is associated with poor regenerative outcomes, and overfilling the defect rather than flush application has been linked to fibrous rather than hyaline-like tissue formation.

Suitability for this combination requires a consultant assessment with MRI cartilage evaluation — measuring defect size, depth, and the condition of the surrounding cartilage — information that cannot reliably be inferred from symptoms alone.

What to expect after a ChondroFiller injection with MSCs

Regardless of defect size or OA grade, the first six weeks after a ChondroFiller injection with MSCs require protected weight-bearing. A 2024 biomechanical in-vitro study confirmed that ChondroFiller cannot reduce load-related stress on opposing cartilage in the early post-implant period — the scaffold needs time to integrate before the joint bears full cyclic load. Crutches or partial weight-bearing during this window is the typical approach, rather than complete immobility.

Functional improvement can begin within weeks. In the 2025 Vienna trial, gains were measurable at two months; standalone ChondroFiller studies show scores continuing to rise through 12 months, with MRI evidence of progressive cartilage maturation — a plateau between six and 12 months is the pattern in published cohort data (MOCART scores of 70–87 at follow-up in knee studies). Structural durability beyond that horizon has not yet been confirmed for the injection route, and is a reasonable question to raise at follow-up.

If improvement falls short of expectations after adequate recovery, the cartilage-restoration pathway remains open. Procedures such as AMIC, MACI, OATS, or osteochondral allograft are still available provided the subchondral bone plate is intact — making early regenerative treatment a sensible starting point rather than one that forecloses surgical options.

Suitability depends on a full cartilage assessment; Lincolnshire Knee accepts patients without referral for consultant evaluation at Sleaford or Grantham.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial. (2023). https://doi.org/10.1186/s13287-023-03359-8 https://doi.org/10.1186/s13287-023-03359-8
4. [4] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
7. [7] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
8. [8] One-Step Cartilage Repair of Full-Thickness Knee Chondral Lesions Using a Hyaluronic Acid–Based Scaffold Embedded With Bone Marrow Aspirate Concentrate: Long-term Outcomes After Mean Follow-up of 14 Years. (2024). https://doi.org/10.1177/03635465241287524 https://doi.org/10.1177/03635465241287524